A carregar...
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
BACKGROUND: Anti‐cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health‐related quality of life (HRQoL) is a direct measure of patient benefit, but is under‐reported. Here we explore associations with reporting of HRQoL data...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7643655/ https://ncbi.nlm.nih.gov/pubmed/32886422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3390 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|